Beneficial Ownership Report · SCHEDULE 13G/A
Yarrow Bioscience, Inc.
YARWNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Yarrow Bioscience, Inc.
- Company CIK
- 0001566044
- Street
- 470 James Street, Suite 007
- City
- New Haven
- State / country code
- CT
- Postal code
- 06513
Statement details
- Amendment number
- 1
- Security class
- Common Stock, $0.0001 par value
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- Perceptive Advisors LLC
- Citizenship / organization
- DE
- Reporting person type
- IA
- Group designation
- b
- Aggregate amount owned
- 1,600,647
- Percent of class
- 9.99
- Sole voting power
- 0
- Shared voting power
- 1,600,647
- Sole dispositive power
- 0
- Shared dispositive power
- 1,600,647
- Aggregate excludes certain shares
- N
Reporting person 2
- Name
- Joseph Edelman
- Citizenship / organization
- X1
- Reporting person type
- IN
- Group designation
- b
- Aggregate amount owned
- 1,600,647
- Percent of class
- 9.99
- Sole voting power
- 0
- Shared voting power
- 1,600,647
- Sole dispositive power
- 0
- Shared dispositive power
- 1,600,647
- Aggregate excludes certain shares
- N
Reporting person 3
- Name
- Perceptive Life Sciences Master Fund, Ltd.
- Citizenship / organization
- E9
- Reporting person type
- CO
- Group designation
- b
- Aggregate amount owned
- 1,600,647
- Percent of class
- 9.99
- Sole voting power
- 0
- Shared voting power
- 1,600,647
- Sole dispositive power
- 0
- Shared dispositive power
- 1,600,647
- Aggregate excludes certain shares
- N
Item 1
Issuer
Yarrow Bioscience, Inc.
Principal executive office address
470 James Street, Suite 007, New Haven, Connecticut, 06513
Item 2
Citizenship
Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.
Filing person
The names of the persons filing this report (collectively, the "Reporting Persons") with respect to the Common Stock, $0.0001 par value (the "Common Stock") of Yarrow Bioscience, Inc. (the "Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")
Principal business or residence address
The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003
Item 3
Not applicable indication
Y
Item 4
Percent of class
Perceptive Advisors: 9.99% Mr. Edelman: 9.99% Master Fund: 9.99%
Amount beneficially owned
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 15,234,944 shares of Common Stock outstanding as of November 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2026, and assume the exercise of pre-funded warrants (the "Pre-Funded Warrants") held by the Reporting Persons for 787,549 shares of Common Stock. Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Common Stock or any Pre-Funded Warrants. The Master Fund directly holds 813,098 shares of Common Stock and 967,361 Pre-Funded Warrants immediately exercisable for shares of Common Stock at an exercise price of $0.0001 per share, subject to the Beneficial Ownership Limitation (as defined below). The terms of the Pre-Funded Warrants provide that the Pre-Funded Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 9.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation permits the Reporting Persons to exercise Pre-Funded Warrants for an aggregate of not more than 787,549 shares of Common Stock. In providing the beneficial ownership information set forth herein, the Reporting Persons have assumed that the aggregate remaining Pre-Funded Warrants held by the Reporting Persons are not exercisable due to the Beneficial Ownership Limitation. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares.
Sole voting power
Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0
Shared voting power
Perceptive Advisors: 1,600,647 Mr. Edelman: 1,600,647 Master Fund: 1,600,647
Sole dispositive power
Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0
Shared dispositive power
Perceptive Advisors: 1,600,647 Mr. Edelman: 1,600,647 Master Fund: 1,600,647
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Signature 1
- Reporting person
- Perceptive Advisors LLC
- Signed
- /s/ Joseph Edelman
- Title
- Joseph Edelman, Managing Member
- Date
- 11/16/2026
Signature 2
- Reporting person
- Joseph Edelman
- Signed
- /s/ Joseph Edelman
- Title
- Joseph Edelman
- Date
- 11/16/2026
Signature 3
- Reporting person
- Perceptive Life Sciences Master Fund, Ltd.
- Signed
- /s/ Joseph Edelman
- Title
- Joseph Edelman, Managing Member
- Date
- 11/16/2026
Company context
Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company is developing YB-101, a potentially first-in-class anti-thyroid stimulating hormone receptor (“TSHR”) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both GD and TED. For more information, visit www.yarrowbioscience.com.
Current securities
Historical securities (1)
Recent company filings
- SCHEDULE 13G/A - filed by Janus Henderson Group Ltd. regarding Yarrow Bioscience, Inc.Nov 16, 2026
- SCHEDULE 13G - filed by AMERIPRISE FINANCIAL INC regarding Yarrow Bioscience, Inc.Nov 16, 2026
- S-8 filingNov 13, 2026
- SCHEDULE 13G/A - filed by Nantahala Capital Management, LLC regarding Yarrow Bioscience, Inc.Nov 13, 2026
- 10-Q filingNov 13, 2026